Return to NG71 Overview

Parkinson’s disease in adults [NG71]

Measuring the use of this guidance

Recommendation: 1.1.3

Because people with Parkinson's disease may develop impaired cognitive ability, communication problems and/or depression, provide them with: both oral and written communication throughout the course of the disease, which should be individually tailored and reinforced as necessary consistent communication from the professionals involved. [2006]

What was measured: Proportion of Parkinson's clinics that had written information about Parkinson’s and Parkinson’s medication routinely available all or most of the time.
Data collection end: September 2015
82.4%
Area covered: National
Source: UK Parkinson's Audit

What was measured: Proportion of people with Parkinson’s disease who received enough information about Parkinson’s on diagnosis.
Data collection end: September 2015
64.9%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.1.6

Offer people with Parkinson's disease an accessible point of contact with specialist services. This could be provided by a Parkinson's disease nurse specialist. [2006]

What was measured: Proportion of people with Parkinson's disease who had access to a Parkinson’s nurse in Elderly Care and Neurology services.
Data collection end: September 2015
94.1%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.1.7

Advise people with Parkinson's disease who drive that they should inform the Driver and Vehicle Licensing Agency (DVLA) and their car insurer of their condition when Parkinson's disease is diagnosed. [2006]

What was measured: Proportion of drivers with Parkinson's disease not been given information regarding contacting the DVLA (or DVA) or their insurance company or were not sure whether they had.
Data collection end: September 2015
26.5%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.2.5

Review the diagnosis of Parkinson's disease regularly, and reconsider it if atypical clinical features develop. (People diagnosed with Parkinson's disease should be seen at regular intervals of 6–12 months to review their diagnosis.) [2006]

What was measured: Proportion of people with Parkinson's disease, attending Elderly Care and Neurology services had received a specialist review in the preceding 12 months
Data collection end: September 2015
98.6%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.4.1

Recognise that impulse control disorders can develop in a person with Parkinson's disease who is on any dopaminergic therapy at any stage in the disease course. [2017]

What was measured: Proportion of patients under neurology on a dopamine agonist monitored for the development of compulsive behaviour.
Data collection end: September 2015
81.5%
Area covered: National
Source: UK Parkinson's Audit

What was measured: Proportion of patients under elderly care on a dopamine agonist monitored for the development of compulsive behaviour.
Data collection end: September 2015
73.1%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.4.2

Recognise that the following are associated with an increased risk of developing impulse control disorders: Dopamine agonist therapy. A history of previous impulsive behaviours. A history of alcohol consumption and/or smoking. [2017]

What was measured: Proportion of patients under neurology on a dopamine agonist monitored for the development of compulsive behaviour.
Data collection end: September 2015
81.5%
Area covered: National
Source: UK Parkinson's Audit

What was measured: Proportion of patients under elderly care on a dopamine agonist monitored for the development of compulsive behaviour.
Data collection end: September 2015
73.1%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.5.1

Advise people with Parkinson's disease who have daytime sleepiness and/or sudden onset of sleep not to drive (and to inform the DVLA of their symptoms) and to think about any occupation hazards. Adjust their medicines to reduce its occurrence, having first sought advice from a healthcare professional with specialist expertise in Parkinson's disease. [2017]

What was measured: Proportion of people with Parkinson's disease who are drivers, that had a documented discussion of the impact of known excessive daytime sleepiness on driving.
Data collection end: September 2015
56.5%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.7.2

Consider referring people who are in the early stages of Parkinson's disease to a physiotherapist with experience of Parkinson's disease for assessment, education and advice, including information about physical activity. [2017]

What was measured: Proportion of people with Parkinson's disease whose time between diagnosis and physiotherapy referral was less than 1 year.
Data collection end: September 2015
27%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.7.3

Offer Parkinson's disease-specific physiotherapy for people who are experiencing balance or motor function problems. [2017]

What was measured: Proportion of Parkinson's clinics that provide physiotherapy services specialising in the treatment of Parkinson’s
Data collection end: September 2015
57.8%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.7.5

Consider referring people who are in the early stages of Parkinson's disease to an occupational therapist with experience of Parkinson's disease for assessment, education and advice on motor and non-motor symptoms. [2017]

What was measured: Proportion of people with Parkinson's disease whose time between diagnosis and occupational therapy referral was less than 1 year.
Data collection end: September 2015
13.9%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.7.7

Consider referring people who are in the early stages of Parkinson's disease to a speech and language therapist with experience of Parkinson's disease for assessment, education and advice. [2017]

What was measured: Proportion of people with Parkinson's disease, on first referral to speech and language therapist , received a full assessment or if a full assessment was not made the reasons for this were documented.
Data collection end: September 2015
92.8%
Area covered: National
Source: UK Parkinson's Audit


Recommendation: 1.9.2

Offer people with Parkinson's disease and their family members and carers (as appropriate) oral and written information about the following, and record that the discussion has taken place: Progression of Parkinson's disease. Possible future adverse effects of Parkinson's disease medicines in advanced Parkinson's disease. Advance care planning, including Advance Decisions to Refuse Treatment (ADRT) and Do Not Attempt Resuscitation (DNACPR) orders, and Lasting Power of Attorney for finance and/or health and social care. Options for future management. What could happen at the end of life. Available support services, for example, personal care, equipment and practical support, financial support and advice, care at home and respite care. [2017]

What was measured: The proportion of people in elderly Care with markers of advanced Parkinson's disease who had a documented discussion about end-of-life care issues
Data collection end: September 2015
25.6%
Area covered: National
Source: UK Parkinson's Audit

What was measured: The proportion of people in neurology with markers of advanced Parkinson's disease who had a documented discussion about end-of-life care issues
Data collection end: July 2015
31.2%
Area covered: National
Source: UK Parkinson's Audit

What was measured: The proportion of people in neurology with markers of advanced Parkinson's disease who had a documented discussion about lasting Power of Attorney
Data collection end: September 2015
27.4%
Area covered: National
Source: UK Parkinson's Audit

What was measured: The proportion of people in elderly care with markers of advanced Parkinson's disease who had a documented discussion about lasting Power of Attorney
Data collection end: September 2015
25.5%
Area covered: National
Source: UK Parkinson's Audit



 Return to NG71 Overview